Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cybin Inc
(NY:
CYBN
)
0.3561
+0.0072 (+2.06%)
Official Closing Price
Updated: 8:00 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Cybin Inc
< Previous
1
2
...
14
15
16
17
18
19
20
21
Next >
Psychedelic Stock Gainers And Losers From February 15, 2022
February 15, 2022
GAINERS: Mind Medicine (NASDAQ:
Via
Benzinga
Cybin Turning Psychedelics-to-Therapeutics(TM) Vision Into Reality
February 15, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice....
Via
Benzinga
Psychedelic Stock Gainers And Losers From February 14, 2022
February 14, 2022
GAINERS: Wellbeing Digital (OTC:
Via
Benzinga
Cybin, MindMed, And Field Trip Health Headline PSYC's First CEO Round Table Event
February 14, 2022
Media company Global Trac Solutions, Inc. (OTCP:PSYC) and authorities behind psychedelic news and information platform Psy...
Via
Benzinga
Psyched: Cathie Wood Invests In Psychedelics Co ATAI, Bill Approved in Utah, AI Startup To 'Design States Of Mind'
February 14, 2022
The psychedelics sector received its latest sign of acceptance from Wall Street with famed investor Cathie Wood taking a position ...
Via
Benzinga
Earnings Scheduled For February 10, 2022
February 10, 2022
Companies Reporting Before The Bell • Canada Goose Hldgs (NYSE:GOOS) is projected to report quarterly earnings at $1.46 per share on revenue of $584.49 million.
Via
Benzinga
Cybin's Vision Strengthens Position In Emerging Wellness Trend
January 28, 2022
Psychedelics pose potential as effective treatments for mental-health issues such as depression, anxiety, and substance abuse Well+Good says psychedelics “poised to change the course of mental health...
Via
Benzinga
Cybin Schedules Release of Q3 Results, Conference Call
January 27, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
Mind Medicine, Cybin Among Top Psychedelic Movers Of Today
February 11, 2022
GAINERS: Revive Therapeutics (OTC: RVVTF) shares closed up 2.51% at $0.22 LOSERS: Mind Medicine (NASDAQ: MNMD) shares closed down 8.09% at $1.25 Cybin (AMEX:CYBN) shares closed down 6.25% at $1.05 ATAI...
Via
Benzinga
Allied, Cybin Among Top Psychedelic Movers Of Today
February 10, 2022
GAINERS: Allied (OTC:ALID) shares closed up 7.39% at $1.89
Via
Benzinga
Cybin Granted US Patent Covering Lead Proprietary Compound
February 10, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
Psychedelic Stock Gainers And Losers From February 9, 2022
February 09, 2022
GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 14.29% at $5.76
Via
Benzinga
Benzinga's Unprecedented Psychedelics Investing Conference Lands In Miami On April 19th
February 09, 2022
The first Benzinga Psychedelics Capital Conference, the premier gathering of psychedelics industry leaders and forward-thinking investors, is coming to the Fontainebleau Miami Beach on April 19, 2022,...
Via
Benzinga
Cybin Obtains U.S. Patent For Is Proprietary Compound Deuterated DMT Aimed At Treating Anxiety Disorders
February 09, 2022
Psychedelics company Cybin Inc. (NEO:CYBN) (AMEX:CYBN) announced that the U.S. Patent and Trademark Office has granted U.S. patent 11,242,318 to the company’s investigational deuterated...
Via
Benzinga
Mindset Pharma, Cybin Among Top Psychedelic Movers Of Today
February 08, 2022
GAINERS: Awakn Life Sciences (OTC:AWKNF) shares closed up 3.51% at $1.62
Via
Benzinga
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
February 07, 2022
GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 9.82% at $1.23
Via
Benzinga
Cybin Marks 2021 Accomplishments, Eyes 'Transformative' 2022
February 07, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
Psyched: Psychedelics ETF Launches On NYSE, Psilocybin Trial Approved For Depression, DMT Study Begins
February 07, 2022
This week saw new triumphs for public companies in the psychedelics space with the creation of a new ETF tracking the sector, which went public in the NYSE.
Via
Benzinga
Psychedelic Stocks Finally In An Upswing
February 06, 2022
The Marijuana & Psychedelic Compounds-Based Drug Stocks Index went up +5.3% last week.
Via
Talk Markets
Small Pharma, Mind Medicine Among Top Psychedelic Movers Of Today
February 04, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 7.29% at $0.20
Via
Benzinga
Field Trip Health, Seelos Therapeutics Among Top Psychedelic Movers Of Today
February 03, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 6.29% at $0.19
Via
Benzinga
Mind Medicine, Allied Among Top Psychedelic Movers Of Today
February 02, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 5.04% at $0.17
Via
Benzinga
Mindset Pharma, Allied Among Top Psychedelic Movers Of Today
February 01, 2022
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 15.70% at $0.69
Via
Benzinga
Cybin's IRB-Approved Study Begins Enrollment This Year
February 01, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Upcoming study supports CYBN’s mission to develop psychedelics...
Via
Benzinga
Magic Mushrooms For Depression: Clinical Trial Of Active Compound Approved For Patients Using Antidepressants
January 31, 2022
Health Canada has allowed a phase 2 clinical trial of psilocybin in patients currently undergoing treatment with traditional antidepressants.
Via
Benzinga
ATAI Life Sciences, Mind Medicine Among Top Psychedelic Movers Of Today
January 31, 2022
GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 7.89% at $5.33
Via
Benzinga
The Psychedelic & Marijuana Drug Stocks Index Dropped -30% In January
January 30, 2022
This article updates the performances of 16 clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses.
Via
Talk Markets
Psychedelic Stock Gainers And Losers From January 28, 2022
January 28, 2022
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 17.86% at $0.57
Via
Benzinga
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
January 27, 2022
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 6.29% at $0.49
Via
Benzinga
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
January 26, 2022
GAINERS: Small Pharma (OTC:
Via
Benzinga
< Previous
1
2
...
14
15
16
17
18
19
20
21
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.